Back to the Top
Hello, I am a grad student in biostatistics. I am doing my thesis in
population pharmacokinetics. If anyone has any information regarding
this subject, I would appreciate hearing about it. Also, since you are
in the field, if you have any suggestions on areas of interest, feel
free to share them. Thank you for your time. Deborah
Back to the Top
[Two replies - db]
From: "medical"
To:
Subject: Re: PharmPK Population pharmacokinetics
Date: Sat, 5 Feb 2000 14:28:57 +0530
X-Priority: 3
Dear Deborrah,
It would be helpful if you went through Averys
drug treatment,which has a section devoted to this topic.Another text would
be Roland and tozer.
Regards,
Amit Taneja
---
From: "Melethil, Srikumaran K."
To: "'PharmPK.-at-.boomer.org'"
Subject: RE: PharmPK Population pharmacokinetics
Date: Sat, 5 Feb 2000 13:49:54 -0600
I would recommend that you do a MEDLINE search. You should easily find some
good review articles that should help you launch your project.
Sri Melethil, Ph.D.
Professor of Pharmaceutics and Medicine
University of Missouri-KC
School of Pharmacy
Room 203-B, 5005 Rockhilll Road
Kansas City, MO 64110
816-235-1794 (fax: 816-235-5190)
Back to the Top
Dear Deborah,
I'm a biostatistician working for Pharsight Corp. We're a company that
provides software tools for population PK/PD analyses, clinical trial
simulation, and related analyses. We also provide PK/PD modelling, clinical
trial design, and project/portfolio decision consulting to most of the top
pharmas.
This is an area that is really growing right, because it helps get drugs to
market faster and cheaper.
You might want to look at our web site (http://www.pharsight.com) for more
details, or if you have more specific questions, don't hesitate to email
me.
Sincerely,
Russell Reeve, PhD
rreeve.-at-.pharsight.com
Jeff Wald wrote:
> Russ - Perhaps you could respond to this individual with some info on
> what we do at Pharsight vis-a-vis population modeling...
>
> -jaw-
Back to the Top
Dear Deborah:
Thanks for your enquiry. You might start by looking at our
web site (see
below), and checking especially our technical reports. It is important to
be aware of the different strengths and weaknesses of the parametric and
the nonparametric approaches. We think it is important, in population
modeling, first, before doing anything else, to start by accurately
determining the error pattern of your assay over its entire working range,
and to describe it as a polynomial, usually of second order. This is
separate from all other sources of intraindividual variability. Next, you
might use a parametric program such as our iterative 2 stage Bayesian one,
to get what we call gamma, the remainder of that intraindividual
variability. After getting both the assay error polynomial and gamma, then
you can use a nonparametric program such as Mallet's NPML or our NPEM, to
get the optimal, most likely, solution to the population analysis problem
(see Alain Mallet) in the discrete joint density, not just summary
statistics such as mean, median, covarances, etc. Not only does this give
you the most likely joint parameter distribution given the raw data in the
population, but it lets you get around the separation principle to develop
optimal dosge regimens which specifically achieve desired target goals with
maximum precision (least weighted squared error). You might look at Clin.
Pharmacokinetics for January 1998. In addition, though, you might also wish
to look at the work of Adrian Smith and Jon Wakefield in the area of Gibbs
sampling methods in population analysis.
Hope this helps. Please let me know if I can do more.
Sincerely,
Roger Jelliffe
Roger W. Jelliffe, M.D. Professor of Medicine, USC
USC Laboratory of Applied Pharmacokinetics
2250 Alcazar St, Los Angeles CA 90033, USA
Phone (323)442-1300, fax (323)442-1302, email= jelliffe.at.hsc.usc.edu
Our web site= http://www.usc.edu/hsc/lab_apk
********************************************************************
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)